Faculty Collaboration Database

The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003 Apr;25(3):215-24

Date

05/14/2003

Pubmed ID

12743627

DOI

10.1358/mf.2003.25.3.769643

Scopus ID

2-s2.0-0037986437 (requires institutional sign-in at Scopus site)   19 Citations

Abstract

Angiogenesis plays a vital role in the pathology of cancer, ischemic diseases and chronic inflammation, among other conditions. Endostatin, a newly found protein that is distributed in some parts of the human body, has been demonstrated to have a strong inhibitory role in angiogenesis. It specifically inhibits the proliferation of endothelial cells and induces their apoptosis both in vitro and in vivo. Preclinical research has proven its effective role in the treatment of various experimental tumors in rodents. Although endostatin therapy has entered phase II clinical trials in the USA, the exact mechanism and its effects on antiangiogenesis, especially the action on the suppression of endothelial cell proliferation and induction of apoptosis, remain unclear. The treatment modality for malignancies and other angiogenesis-related diseases still requires further analysis.

Author List

Ren B, Höti N, Rabasseda X, Wang YZ, Wu M

MESH terms used to index this publication - Major topics in bold

Angiogenesis Inhibitors
Animals
Collagen
Endostatins
Humans
Liver
Neoplasms
Peptide Fragments